Skip to main content

Sinecatechins (Monograph)

Brand name: Veregen
Drug class: Skin and Mucous Membrane Agents, Miscellaneous
CAS number: 188265-33-0


Antioxidant; a green tea extract consisting predominantly of catechins.

Uses for Sinecatechins

External Genital and Perianal Human Papillomavirus Warts

Treatment of external genital and perianal warts (condylomata acuminata) caused by human papillomavirus (HPV) in immunocompetent patients.

CDC recommends that external HPV genital warts be treated with a self-administered topical therapy (imiquimod, podofilox, sinecatechins), a topical therapy administered by a health-care provider (podophyllum resin, trichloroacetic acid [TCA], bichloroacetic acid [BCA]), or a surgical technique (cryotherapy, electrosurgery, surgical excision).

Should not be used for treatment of urethral, intravaginal, cervical, rectal, or intra-anal HPV disease; safety and efficacy not established.

Sinecatechins Dosage and Administration


Topical Administration

Apply topically to the skin as a 15% ointment. For external use only.

Avoid contact with the eyes; do not administer orally, intravaginally, or intra-anally. Do not apply to open wounds.

Wash hands before and after application. Apply a thin layer to each wart with the finger(s), dabbing to ensure complete coverage. Do not use bandages, occlusive dressings, or wrappings.

Uncircumcised males treating warts under the foreskin should retract the foreskin and clean the area daily.

Washing ointment from the treated area prior to the next application is not necessary. If bathing or washing the treatment area, apply ointment afterwards. (See Advice to Patients.)



HPV Infections
External Genital and Perianal HPV Warts

Apply a 0.5-cm strand of ointment to each wart 3 times daily, dabbing with fingers to ensure complete coverage and leaving a thin film on warts.

Continue therapy until all warts have completely cleared or for a maximum of 16 weeks.

Safety and efficacy of multiple treatment courses not established.

Prescribing Limits


HPV Infections
External Genital and Perianal HPV Warts

Maximum of 16 weeks.

Special Populations

No special population dosage recommendations.

Cautions for Sinecatechins



Other Forms of HPV Disease

Safety and efficacy not established for treatment of urethral, intravaginal, cervical, rectal, or intra-anal HPV disease.

Dermatologic Effects

Do not apply to open wounds. Local skin reactions occur frequently. (See Common Adverse Effects under Cautions.) Continue therapy when severity of the local skin reaction is acceptable. In case of severe local reactions (i.e., pruritus), wash area with mild soap and water to remove the ointment; withhold further doses and notify clinician.

Avoid exposure of the genital and perianal area to sunlight or ultraviolet light; effects of such light not studied.

Immunologic Effects

Safety and efficacy in immunosuppressed patients not established.

Specific Populations


Category C.


Not known whether topical sinecatechins is distributed into human milk.

Pediatric Use

Safety and efficacy not established in pediatric patients. Consult a clinician before using in children <12 years of age.

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.

Common Adverse Effects

Erythema, pruritus, burning, pain/discomfort, erosion/ulceration, edema, induration, vesicular rash.

Drug Interactions

No formal drug interaction studies to date.

Sinecatechins Pharmacokinetics



Pharmacokinetics after topical application not fully characterized. Data suggest that systemic exposure to catechins following repeated topical application of sinecatechins ointment probably is less than that observed after single ingestion of 400 mL of green tea.



Not known whether distributed into milk following topical application.





Before dispensing to patient: 2–8°C. After dispensing, store refrigerated or at temperatures <25°C. Do not freeze.


Advice to Patients


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.



Dosage Forms


Brand Names







AHFS DI Essentials™. © Copyright 2024, Selected Revisions April 4, 2011. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

Reload page with references included